Quarterly ResultMay 14, 2026, 04:09 PM
CV Sciences Q1 Revenue $3.2M; Adjusted EBITDA Loss Narrows
AI Summary
CV Sciences, Inc. reported Q1 2026 financial results with revenue of $3.2 million, an 11.4% decrease year-over-year, primarily due to restrictive regulations. Despite the revenue decline, the company achieved a gross margin of 48.9% and reduced its adjusted EBITDA loss to $0.1 million from $0.3 million in Q1 2025. The company also completed a successful debt restructuring to strengthen its financial position and launched a new product, EMPOWR. Management expressed optimism for gross margin improvement in the second half of 2026 and is focused on profitability and strategic acquisitions.
Key Highlights
- Completed successful debt restructuring to strengthen financial position.
- Launched EMPOWR, a new plant-based protein and creatine formula.
- Q1 2026 revenue decreased 11.4% to $3.2 million from $3.6 million in Q1 2025.
- Gross margin improved to 48.9% in Q1 2026 from 46.0% in Q1 2025.
- Adjusted EBITDA loss narrowed to $0.1 million in Q1 2026 from $0.3 million in Q1 2025.
- Operating expenses reduced by 13.3% to $1.9 million in Q1 2026.
- Net loss for Q1 2026 was $(643) thousand, compared to $(109) thousand in Q1 2025.
- Cash balance stood at $0.3 million at quarter end.